DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER (DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER).
Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-1 adrenergic receptors of the heart, increasing contractility and cardiac output. It also has mild beta-2 and alpha-1 receptor activity.
| Metabolism | Primarily hepatic via catechol-O-methyltransferase (COMT) to inactive metabolites; also conjugation with glucuronic acid. |
| Excretion | Primarily renal excretion of metabolites (catechol-O-methyltransferase conjugates) and unchanged drug: approximately 80% renal, 20% biliary/fecal. Less than 5% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 2 minutes for the parent drug (dobutamine) due to rapid metabolism by COMT. In clinical context, the effect half-life is about 2–3 minutes, requiring continuous intravenous infusion to maintain steady-state concentrations. |
| Protein binding | Approximately 20% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.2 L/kg, indicating limited distribution primarily into extracellular fluid and minimal tissue binding. This low Vd reflects rapid clearance and short half-life. |
| Bioavailability | Dobutamine is not effective when given orally (bioavailability <5% due to extensive first-pass metabolism by COMT and MAO). Only intravenous route is clinically used; bioavailability is 100% by IV infusion. |
| Onset of Action | Onset of action following intravenous administration: 1–2 minutes. Peak effect occurs within 10 minutes of initiating a continuous infusion. |
| Duration of Action | Duration of action is short, with hemodynamic effects dissipating within 10–15 minutes after discontinuation of infusion. Clinical effects are closely tied to infusion rate and plasma concentration. |
Continuous IV infusion: 2.5 to 20 mcg/kg/min; titrate to desired hemodynamic response. Maximum dose: 40 mcg/kg/min.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; dobutamine is primarily metabolized in tissues. |
| Liver impairment | No specific guidelines; clearance may be reduced in severe hepatic impairment. Monitor hemodynamics and titrate cautiously. |
| Pediatric use | Continuous IV infusion: 2.5 to 15 mcg/kg/min; titrate to effect. For neonates, start at lower end of range. |
| Geriatric use | No specific dose adjustment; start at lower end of dosing range (2.5 mcg/kg/min) due to potential decreased cardiovascular reserve and increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER (DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Breastfeeding safety: Not recommended unless essential. Dobutamine is likely excreted into breast milk; M/P ratio not available. High maternal doses may expose infant to sympathomimetic effects (tachycardia, hypertension). Use only if potential benefit justifies risk. Monitor infant for adverse effects. |
| Teratogenic Risk | Dobutamine hydrochloride in dextrose 5% is a sympathomimetic amine used intravenously for inotropic support. Fetal risk: In pregnant women, use only if clearly needed. Animal reproduction studies are not available. Dobutamine may increase uterine contractility and reduce uteroplacental perfusion. First trimester: Caution; avoid if possible. Second and third trimesters: May be used for acute maternal hemodynamic instability; monitor for fetal distress (e.g., tachycardia, hypoxia). There is no evidence of teratogenicity in humans, but data are limited. |
■ FDA Black Box Warning
No FDA boxed warnings.
| Common Effects | High blood pressure Insomnia difficulty in sleeping |
| Serious Effects |
["Hypersensitivity to dobutamine or any component","Idiopathic hypertrophic subaortic stenosis (IHSS)","Patients with atrial fibrillation or flutter with rapid ventricular response (may increase AV conduction)"]
| Precautions | ["May increase heart rate and blood pressure, potentially causing tachycardia and hypertension","May exacerbate ischemia in patients with coronary artery disease","Risk of cardiac arrhythmias, including ventricular ectopy","Hypovolemia should be corrected before use","Contains dextrose; caution in diabetes mellitus","Monitor electrolytes, especially potassium","Use in pregnancy only if clearly needed"] |
Loading safety data…
| Fetal Monitoring | Continuous ECG, blood pressure, heart rate, and oxygen saturation during infusion. Monitor maternal fluid status, electrolytes, and renal function. Fetal monitoring: continuous fetal heart rate and uterine activity (tocodynamometer) when feasible. Assess uteroplacental perfusion via Doppler if indicated. Observe for maternal arrhythmias, hypertension, or ischemia. |
| Fertility Effects | No human data on fertility effects. Animal studies not available. Dobutamine's beta-1 agonist activity may theoretically affect reproductive function via altered autonomic tone; no known significant impact on human fertility. |